




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application Number	10/501,411
Filing Date	July 12, 2004
First Named Inventor	Micheal Cowley
Group Art Unit	1656
Examiner Name	Rooke, Agnes
Attorney Docket Number	AI 9248US

Sheet 1 of 20

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
/AR/		3,773,919		Boswell, et al.	11-20-1973	
		4,002,531		Royer	01-11-1977	
		4,175,122		Lazarus	11-20-1979	
		4,179,337		Davis, et al.	12-18-1979	
		4,223,017		Lazarus	09-16-1980	
		4,355,025		Lazarus	10/19/1982	
		4,485,045		Regen	11-27-1984	
		4,544,545		Ryan, et al.	10-01-1985	
		4,619,794		Hauser	10-28-1986	
		4,701,441		Kalra	10/20/1987	
		4,829,076		Szilagyi, et al.	05-09-1989	
		5,021,234		Ehrenfeld	06-04-1991	
		5,026,685		Boublik, et al.	06-25-1991	
		5,122,614		Zalipsky	06-16-1992	
		5,284,839		Siren, et al.	02-08-1994	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
/AR/		DE	3 218 121		Leskovar	11-17-1983		
		EP	0 036 676		The Regents of the University of California	09-30-1981		
		EP	0 052 322		Gersonde, et al.	05-26-1982		
		EP	0 058 481		Imperial Chemical Industries PLC	08-25-1982		
		EP	0 102 324		Ciba-Geigy AG	03-07-1984		
Examiner's Signature	/Agnes Rooke/ (02/11/2008)					Date Considered	02/11/2008	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number		10/501,411
				Filing Date		July 12, 2004
				First Named Inventor		Micheal Cowley
				Group Art Unit		
				Examiner Name		
Sheet	2	of	20	Attorney Docket Number		AI 9248US

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
/AR/		5,349,052		Delgado, et al.	09-20-1994	
		5,428,128		Mensi-Fattohi, et al.	06-27-1995	
		5,574,010		McFadden	11-12-1996	
		5,604,203		Balasubramaniam	02-18-1997	
		5,635,503		Poindexter, et al.	06-03-1997	
		5,643,575		Martinez, et al.	07-01-1997	
		5,696,093		Tseng, et al.	12-09-1997	
		5,700,486		Canal, et al.	12-23-1997	
		5,728,396		Peery, et al.	03-17-1998	
		5,880,131		Greenwald, et al.	03-09-1999	
		5,889,016		Bruce, et al.	03-30-1999	
		5,912,227		Croom, et al.	06/15/1999	
		5,919,901		Hu, et al.	07/06/1999	
		5,936,092		Shen, et al.	08-10-1999	
		5,939,380		Wang	08-17-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
/AR/		EP	0 133 988		Hoechst AG	03-13-1985		
		EP	0 143 949		Terumo Corporation	06-12-1985		
		EP	0 267 050		Research Development Foundation	05-11-1988		
		EP	0 401 384		Kirin Amgen, Inc.	12-12-1990		
		JP	60-007934		Dai Ichi Seiyaku Co Ltd	01-16-1985		
		PCT	WO 80/01882		Granger	09-18-1980		
Examiner's Signature		/Agnes Rooke/ (02/11/2008)				Date Considered	02/11/2008	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/501,411		
		Filing Date	July 12, 2004		
		First Named Inventor	Micheal Cowley		
		Group Art Unit			
		Examiner Name			
Sheet	3	of	20	Attorney Docket Number	AI 9248US

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
/AR/		5,965,392		Hun, et al.	10/12/1999	
		5,989,920		Gerald, et al.	11/23/1999	
		5,993,414		Haller	11-30-1999	
		6,001,836		Poindexter, et al.	12-14-1999	
		6,001,970		Cascieri, et al.	12/14/1999	
		6,046,167		Balasubramaniam	04/04/2000	
		6,048,900		Connell, et al.	04-11-2000	
		6,093,692		Shen, et al.	07-25-2000	
		6,127,355		Greenwald, et al.	10-03-2000	
		6,140,354		Dax, et al.	10-31-2000	
		6,191,102		Dimarchi, et al.	02-20-2001	
		6,201,025		Dax, et al.	03-13-2001	
		6,218,408		Marzabadi, et al.	04-17-2001	
		6,225,330		Marzabadi, et al.	05-01-2001	
		6,225,445		Shen, et al.	05-01-2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁸
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
/AR/		PCT	WO 93/09227		Garvan Institute of Medical Research	05-13-1993		
		PCT	WO 93/19175		Thorens	09-30-1993		
		PCT	WO 94/22467		University of Cincinnati	13/10/1994		
		PCT	WO 95/06058		Royal Free Hospital School of Medicine	03-02-1995		

Examiner's Signature	/Agnes Rooke/ (02/11/2008)	Date Considered	02/11/2008
----------------------	----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/501,411		
		Filing Date	July 12, 2004		
		First Named Inventor	Micheal Cowley		
		Group Art Unit			
Examiner Name					
Sheet	4	of	20	Attorney Docket Number	AI 9248US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
/AR/		6,316,203		Gerald, et al.	11/13/2001
		6,340,683		Marzabadi, et al.	01-22-2002
		6,348,472		Poindexter, et al.	02-19-2002
		6,355,478		Baez, et al.	03-12-2002
		6,372,743		Darrow, et al.	04-16-2002
		6,380,224		Dax, et al.	04-30-2002
		6,391,877		Islam, et al.	05-21-2002
		6,391,881		Sit	05-21-2002
		6,399,631		Elliot, et al.	06-04-2002
		6,407,120		Carpino, et al.	06-18-2002
		6,410,707		Wagner, et al.	06-25-2002
		6,410,792		Connell, et al.	06-25-2002
		6,420,532		Gerald, et al.	07-16-2002
		6,432,960		Sit, et al.	08-13-2002
		6,436,091		Harper, et al.	08-20-2002
		6,444,675		Sit	09-03-2002

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office. ³	Number ⁴	Kind Code ⁵ (if known)		
/AR/		PCT	WO 96/22783		North Carolina State University	01/08/1996
		PCT	WO 97/37998		Bayer Corporation	16/10/1997
		PCT	WO 97/46579		Peptech Ltd and CRC for Biopharmaceutical Research Ltd.	11/12/1997

Examiner's Signature	/Agnes Rooke/ (02/11/2008)	Date Considered	02/11/2008
----------------------	----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
				Application Number		10/501,411	
				Filing Date		July 12, 2004	
				First Named Inventor		Micheal Cowley	
				Group Art Unit			
				Examiner Name			
Sheet	5	of	20	Attorney Docket Number		AI 9248US	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
/AR/		6,447,743		Devic, et al	09-10-2002	
↓		6,447,753		Edwards, et al.	09-10-2002	
		6,620,910		Calas, et al.,	09-16-2003	
		60/256,216		Pittner et al	12-14-2000	
		60/324,406		Cowley, et al.	09-24-2001	
		2002/0141985		Pittner et al	10/03/02	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office. ³	Number ⁴	Kind Code ⁵ (if known)			
/AR/		PCT	WO 98/20885		University of Cincinnati	05-22-1998	
↓		PCT	WO 98/32466		Polymasc Pharmaceuticals	07-30-1998	
		PCT	WO 99/43707		Novo Nordisk A/S	09-02-1999	
		PCT	WO 00/34236		University of Southern California	06-15-2000	
		PCT	WO 00/42026		Novo Nordisk A/S	07-20-2000	
		PCT	WO 00/47219		Ontogeny, Inc.	08-17-2000	

Examiner's Signature	/Agnes Rooke/ (02/11/2008)	Date Considered	02/11/2008
----------------------	----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Substitute for form 1449A/PTO <h1 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1> <p style="text-align: center;">(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/501,411
				Filing Date	July 12, 2004
				First Named Inventor	Micheal Cowley
				Group Art Unit	
				Examiner Name	
Sheet	6	of	20	Attorney Docket Number	AI 9248US

[illegible]

Examiner's Signature	/Agnes Rooke/ (02/11/2008)	Date Considered	02/11/2008
----------------------	----------------------------	-----------------	------------

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/501,411
				Filing Date	July 12, 2004
				First Named Inventor	Micheal Cowley
				Group Art Unit	
				Examiner Name	
Sheet	7	of	20	Attorney Docket Number	AI 9248US

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/AR/		ABUCHOWSKI, et al., "Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates," <i>Cancer Biochem Biophys.</i> , 7(2):175-86 (1984).	
		ADRIAN, et al., "Distribution and postprandial release of porcine peptide YY," <i>J Endocrinol.</i> , 113:11-4, (1987).	
		ADRIAN, et al., "Release of peptide YY (PYY) after resection of small bowel, colon, or pancreas in man," <i>Surgery</i> , 101(6):715-9 (1987).	
		ADRIAN, et al., "Elevated plasma peptide YY in human neonates and infants," <i>Pediatr Res.</i> , 20(12):1225-7 (1986).	
		ADRIAN, et al., "Peptide YY abnormalities in gastrointestinal diseases," <i>Gastroenterology</i> , 90:379-84 (1986).	
		ADRIAN, et al., "Plasma peptide YY (PYY) in dumping syndrome," <i>Digestive Diseases & Sciences</i> , 30(12):1145-8 (1985).	
		ADRIAN, et al., "Effect of peptide YY on gastric, pancreatic, and biliary function in humans," <i>Gastroenterology</i> , 89:494-9 (1985).	
		ADRIAN et al., "Human distribution and release of a putative new gut hormone, peptide yy" <i>Gastroenterology</i> 89:1070-1077 (1985).	
		ALLEN, et al., "Effects of peptide YY and neuropeptide Y on gastric emptying in man," <i>Digestion</i> , 30:255-62 (1984).	
		ALLEN, et al., "Radioimmunoassay of neuropeptide Y," <i>Regul Pept.</i> , 8(1):61-70 (1984).	
		ALLEN, et al., "Two novel related peptides, neuropeptide Y (NPY) and peptide YY (PYY) inhibit the contraction of the electrically stimulated mouse vas deferens," <i>Neuropeptides</i> , 3:71-7 (1982).	
		ASAKAWA, et al., "Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice," <i>Peptides</i> , 20:1445-8 (1999)	
		BAGNOL, et al., "Anatomy of an endogenous antagonist: relationship between Agouti-related protein and proopiomelanocortin in brain," <i>J Neurosci</i> , 19(18)RC26:1-7 (1999).	
		BALASUBRAMANIAM, et al., "Syntheses and receptor affinities of partial sequences of peptide yy (pyy)" <i>Pept Res.</i> , 1(1):32-5 (1998).	
		BARLOW and DIETZ, "Obesity Evaluation and Treatment: Expert Committee recommendations," <i>Pediatrics</i> , 102:E29-40 (1998).	

Examiner's Signature	/Agnes Rooke/ (02/11/2008)	Date Considered	02/11/2008
----------------------	----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/501,411
				Filing Date	July 12, 2004
				First Named Inventor	Micheal Cowley
				Group Art Unit	
				Examiner Name	
Sheet	8	of	20	Attorney Docket Number	AI 9248US

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/AR/		BARRACHINA, et al., "Leptin-induced decrease in food intake is not associated with changes in gastric emptying in lean mice" <i>Am. J. Physiol.</i> , 272:R1007-11 (1997).	
		BARSH, et al., "Genetics of body-weight regulation," <i>Nature</i> , 404(6778):644-51 (2000).	
		BATTERHAM and BLOOM, "The gut hormone peptide YY regulates appetite," <i>Ann N Y Acad Sci.</i> , 994:162-8 (2003).	
		BATTERHAM, et al., "Gut hormone PYY(3-36) physiologically inhibits food intake," <i>Nature</i> , 418(6898):650-4 (2002).	
		BECK-SICKINGER and JUNG, "Structure-activity relationships of neuropeptide y analogues with respect to Y ₁ and Y ₂ receptors" <i>Biopolymers</i> , 37:123-142 (1995).	
		BEER, et al., "The effect of a 72-h fast on plasma levels of pituitary, adrenal, thyroid, pancreatic and gastrointestinal hormones in healthy men and women," <i>J Endocrinol</i> , 120:337-50 (1989).	
		BERGLUND, MM, "Binding Properties of Three Neuropeptide Y Receptor Subtypes from Zebrafish: Comparison with Mammalian Y1 Receptors" <i>Biochem Pharmacol</i> , 60(12):1815-22 (2000).	
		BROBERGER, et al., "Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus" <i>Neuroendocrinology</i> , 66:393-408 (1997).	
		BUCHWALD, et al., "Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis" <i>Surgery</i> , 88:507-16 (1980).	
		BUTLER, et al., "Melanocortin-4 receptor is required for acute homeostatic responses to increased dietary fat" <i>Nature Neuroscience</i> , 4:605-611 (2001).	
		BUTLER, et al., "A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse," <i>Endocrinology</i> , 141:3518-21 (2000).	
		CABRELE, et al., "Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family" <i>J Pept Sci.</i> , 6(3):97-122 (2000).	
Examiner's Signature	/Agnes Rooke/ (02/11/2008)		Date Considered 02/11/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/501,411
				Filing Date	July 12, 2004
				First Named Inventor	Micheal Cowley
				Group Art Unit	
				Examiner Name	
Sheet	9	of	20	Attorney Docket Number	AI 9248US

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/AR/		CALAM, et al., "Regional differences in concentrations of regulatory peptides in human colon mucosal biopsy," <i>Digestive Diseases & Sciences</i> , 34(8):1193-8 (1989).	
		CALICETI, et al., "Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers," <i>Bioconjug Chem.</i> , 10(4):638-46 (1999).	
		CAMPBELL, et al., "Oxygen-dependent K ⁺ influxes in Mg ²⁺ -clamped equine red blood cells," <i>J. Physiol.</i> 515:431-7 (1999).	
		CAMPFELD, et al., "Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks," <i>Science</i> , 269:546-9 (1995).	
		CHELIKANI, et al., "Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats," <i>Endocrinology</i> , 146(2):879-88 (2005).	
		CLAPHAM, et al., "Anti-obesity drugs: a critical review of current therapies and future opportunities," <i>Pharmacol Ther.</i> , 89(1):81-121 (2001).	
		CLINICAL Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report. National Institutes of health, <i>Obesity Research</i> 6(Suppl 2):51S-209S (1998).	
		COMUZZIE, et al., "A major quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2," <i>Nature Genetics</i> , 15:273-6 (1997).	
		CONE, "The central melanocortin system and energy homeostasis," <i>Trends Endocrinol. Metab.</i> , 10:211-16 (1999).	
		COWLEY, et al., "Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus" <i>Nature</i> , 411:480-484 (2001).	
		COWLEY, et al., "Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat," <i>Neuron</i> , 24:155-63 (1999).	
		COX and RANDICH, "Enhancement of feeding suppression by PYY(3-36) in rats with area postrema ablations," <i>Peptides</i> , 25(6):985-9 (2004).	
Examiner's Signature		/Agnes Rooke/ (02/11/2008)	Date Considered
			02/11/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/501,411
				Filing Date	July 12, 2004
				First Named Inventor	Micheal Cowley
				Group Art Unit	
				Examiner Name	
Sheet	10	of	20	Attorney Docket Number	AI 9248US

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/AR/		CSIFFARY, et al., "Neuropeptide Y innervation of ACTH-immunoreactive neurons in the arcuate nucleus of rats: a correlated light and electron microscopic double immunolabeling study," <i>Brain Research</i> , 506:215-222 (1990).	
		DELGADO, et al., "The uses and properties of PEG-linked proteins," <i>Crit Rev Ther Drug Carrier Syst.</i> , 9(3-4):249-304 (1992).	
		DONCKIER, et al., "Age-related changes in regulatory peptides in rectal mucosa," <i>Acta Gastro-Enterologica Belgica</i> , 50(4):405-10 (1987).	
		DOODS, H.N., "Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226" <i>J Pharmacol Exp Ther.</i> , 275(1):136-42 (1995).	
		DREBORG, et al., "Immunotherapy with monomethoxypolyethylene glycol modified allergens," <i>Crit Rev Ther Drug Carrier Syst.</i> , 6(4):315-65 (1990).	
		DUMONT, et al., "Characterization of a selective neuropeptide Y/peptide YY Y2 receptor radioligand" <i>Society for Neuroscience Abstracts</i> , 19:726 (1993).	
		EBERLEIN, et al., "A new molecular form of PYY: structural characterization of human PYY(3-36) and PYY(1-36)" <i>Peptides</i> , 10:797-803 (1989).	
		EDWARDS, et al., "Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers" <i>Am. J. Physiol. Endocrinol. Metab.</i> , 281:E155-E166, (2001).	
		EKBLAD and SUNDLER, "Distribution of pancreatic polypeptide and peptide YY," <i>Peptides</i> , 23:251-61 (2002).	
		ELIAS, et al., "Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area," <i>Neuron</i> , 23:775-86 (1999).	
		ENG, et al., "Isolation and characterization of exendin-4, an exendin-3 analogue, from <i>Heloderma suspectum</i> venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas," <i>J Biol Chem.</i> , 267(11):7402-5 (1992).	
		EPSTEIN, et al., "Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor" <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 82:3688-3692 (1985).	

Examiner's Signature	/Agnes Rooke/ (02/11/2008)	Date Considered	02/11/2008
----------------------	----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/501,411		
		Filing Date	July 12, 2004		
		First Named Inventor	Micheal Cowley		
		Group Art Unit			
		Examiner Name			
Sheet	11	of	20	Attorney Docket Number	AI 9248US

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/AR/		FAN, et al., "Role of melanocortinergic neurons in feeding and the agouti obesity syndrome," <i>Nature</i> , 385:165-8 (1997).	
		FAROOQI, et al., "Effects of recombinant leptin therapy in a child with congenital leptin deficiency," <i>New Engl. J. Med.</i> , 341:879-84 (1999).	
		FERRI, et al., "Intramural distribution of regulatory peptides in the sigmoid-recto-anal region of the human gut," <i>Gut</i> , 29:762-8 (1988).	
		FOURNIER, et al., "Conformational and biological studies of neuropeptide Y analogs containing structural alterations" <i>Mol Pharmacol.</i> , 45(1):93-101 (1994).	
		FRANCIS, et al., "PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques," <i>Int J Hematol.</i> , 68(1):1-18 (1998).	
		FRIED, et al., "Temporal relationships of cholecystokinin release, pancreaticobiliary secretion, and gastric emptying of a mixed meal," <i>Gastroenterology</i> , 95:1344-50 (1988).	
		FUEßL, et al., "Peptide YY in Diabetes Treated Chronically with an Intestinal Glucosidase Inhibitor," <i>Klinische Wochenschrift</i> , 66:985 (1988).	
		FUESSL, et al., "The effect of a long-acting somatostatin analogue (SMS 201-995) on intermediary metabolism and gut hormones after a test meal in normal subjects," <i>Aliment. Pharmacol. Therap.</i> , 1:321-30 (1987).	
		GEHLERT, et al., "Multiple receptors for the pancreatic polypeptide (pP-fold) family: Physiological implications" <i>Proc Soc Exp Biol Med.</i> , 218:7-22 (1998).	
		GHATEI, et al., "Fermentable dietary fibre, intestinal microflora and plasma hormones in the rat," <i>Clinical Science</i> , 93:109-12 (1997).	
		GLAUM, et al., "Leptin, the Obese Gene Product, Rapidly Modulates Synaptic Transmission in the Hypothalamus," <i>Mol. Pharmacol.</i> , 50:230-235 (1996).	
		GOODLAD, et al., "Does the response of the intestinal epithelium to keratinocyte growth factor vary according to the method of administration?" <i>Regul Pept</i> , 87:83-90 (2000).	

Examiner's Signature	/Agnes Rooke/ (02/11/2008)	Date Considered	02/11/2008
----------------------	----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/501,411
				Filing Date	July 12, 2004
				First Named Inventor	Micheal Cowley
				Group Art Unit	
				Examiner Name	
Sheet	12	of	20	Attorney Docket Number	AI 9248US

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/AP/		GOODLAD, et al., "Insulin and intestinal epithelial cell proliferation," <i>Exp Physiol.</i> 78(5):697-705 (1993).	
		GOODLAD, et al., "Glucagon 1-21 reduces intestinal epithelial cell proliferation in parenterally fed rats," <i>Experimental Physiology</i> , 76:943-9 (1991).	
		GOODLAD, et al., "Is peptide YY trophic to the intestinal epithelium of parenterally fed rats," <i>Digestion</i> , 46(S2):177-81 (1990). GOODLAD, et al., "	
		GOODLAD, et al, "Plasma enteroglucagon, gastrin and peptide YY in conventional and germ-free rats refed with a fibre-free or fibre-supplemented diet," <i>Q J Exp Physiol.</i> , 74(4):437-42 (1989).	
		Proliferative effects of 'fibre' on the intestinal epithelium: relationship to gastrin, enteroglucagon and PYY," <i>Gut</i> , 28(S1):221-6 (1987).	
		GOOGLAD, et al, "Effects of an elemental diet, inert bulk and different types of dietary fibre on the response of the intestinal epithelium to refeeding in the rat and relationship to plasma gastrin, enteroglucagon, and PYY concentrations", <i>Gut</i> , 28:171-80 (1987)	
		GRAFFNER, et al., "Effects of physiological increases of plasma noradrenaline on gastric acid secretion and gastrointestinal hormones, <i>Digestive Diseases & Sciences</i> , 32(7):715-9 (1987).	
		GRANDT, et al., "Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36" <i>Regulatory Peptides</i> , 67(1):151-159 (1996).	
		GRANDT, et al., "Characterization of two forms of peptide YY, PYY(1-36) and PYY(3-36), in the rabbit" <i>Regul. Pept.</i> , 51:815-20 (1994).	
		GRANDT, et al., "Neuropeptide Y 3-36 is an endogenous ligand selective for Y2 receptors" <i>Peptides</i> , 15(5):33-37 (1994).	
		GRIECO, et al., "D-Amino acid scan of gamma-melanocyte-stimulating hormone: importance of Trp(8) on human MC3 receptor selectivity," <i>J. Med. Chem.</i> , 43:4998-5002 (2000).	
		GROVE, et al., "Neuropeptide Y Y5 receptor protein in the cortical/limbic system and brainstem of the rat: expression on gamma-aminobutyric acid and corticotropin-releasing hormone neurons," <i>Neuroscience</i> , 100(4):731-40 (2000).	

Examiner's Signature	/Agnes Rooke/ (02/11/2008)	Date Considered	02/11/2008
----------------------	----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/501,411
				Filing Date	July 12, 2004
				First Named Inventor	Micheal Cowley
				Group Art Unit	
				Examiner Name	
Sheet	13	of	20	Attorney Docket Number	AI 9248US

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/AR/		GRUNDEMAR, et al., "Ligand binding and functional effects of systematic double D-amino acid residue substituted neuropeptide Y analogs on Y1 and Y2 receptor types" <i>Regulatory Peptides</i> , 62:131-136 (1996).	
		HAGAN, "Peptide YY: a key mediator of orexigenic behavior," <i>Peptides</i> , 23:377-82 (2002).	
		HAGER, et al., "A genome-wide scan for human obesity genes reveals a major susceptibility locus on chromosome 10," <i>Nature Genetics</i> , 20, 304-8 (1998).	
		HAKANSSON, et al., "Leptin receptor immunoreactivity in chemically defined target neurons of the hypothalamus" <i>J Neurosci.</i> , 18:559-72 (1998).	
		HAMMER, et al., "Pituitary-Specific and Hormonally Regulated Gene Expression Directed by the Raf Proiomelanocortin Promoter in Transgenic Mice," <i>Mol. Endocrin.</i> , 4(11), 1689-97 (1990).	
		HARDING, et al., "Identification and characterization of the emetic effects of peptide YY," <i>Peptides</i> , 10:21-4 (1989).	
		HAYNES, et al., "Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic," <i>Hypertension</i> , 33(1):542-7 (1999).	
		HAYNES, et al., "Receptor-mediated regional sympathetic nerve activation by leptin," <i>J. Clin. Invest.</i> , 100:270-8 (1997)	
		HEISLER, et al., "Activation of central melanocortin pathways by fenfluramine," <i>Science</i> , 297(5581):609-11 (2002).	
		HOFFMAN, et al., "c-Fos and related immediate early gene products as markers of activity in neuroendocrine systems," <i>Front. Neuroendocrinol.</i> , 14:173-213 (1993).	
		HORVATH, et al., "Heterogeneity in the neuropeptide Y-containing neurons of the rat arcuate nucleus: GABAergic and non-GABAergic subpopulations," <i>Brain Res.</i> , 756:283-6 (1997).	
		HORVATH, et al., "Gabaergic and Cathcholaminergic Innervation of Mediobasal Hypothalamic β -Endorphin Cells Projecting to the Medial Preoptic Area." <i>Neuroscience</i> , 51:391-9 (1992).	
		HWANG, et al., "Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study" <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 77:4030-4034 (1980).	

Examiner's Signature	/Agnes Rooke/ (02/11/2008)	Date Considered	02/11/2008
----------------------	----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/501,411		
		Filing Date	July 12, 2004		
		First Named Inventor	Micheal Cowley		
		Group Art Unit			
		Examiner Name			
Sheet	14	of	20	Attorney Docket Number	AI 9248US

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/AR/		IYENGAR, et al., "Characterization of neuropeptide Y-induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding?" <i>J Pharmacol Exp Ther.</i> , 289(2):1031-40 (1999).	
		JEQUIER, et al., "Energy, obesity, and body weight standard," <i>Am. J. Clin.Nutr.</i> , 45:1035-47 (1987).	
		KALRA, et al., "Interacting appetite-regulating pathways in the hypothalamic regulation of body weight" <i>Endocr. Rev.</i> , 20:68-100 (1999).	
		KANATANI, A., "L-152,804: Orally active and selective neuropeptide Y Y5 receptor antagonist" <i>Biochem Biophys Res Commun.</i> , 272(1):169-73 (2000).	
		KEIRE, et al., "Primary structures of PYY, [Pro(34)]PYY, and PYY-(3-36) confer different conformations and receptor selectivity," <i>Am. J. Physiol. Gastrointest. Liver Physiol.</i> , 279:G126-31 (2000).	
		KELLY, et al., "Opioids Hyperpolarize β -Endorphin Neurons via μ -Receptor Activation of a Potassium Conductance," <i>Neuroendocrinology</i> , 52:268-75 (1990).	
		KENCHIAIAH, et al., "Obesity and the risk of heart failure," <i>N Engl J Med.</i> , 347(5):305-13 (2002).	
		KIM, et al., "Hypothalamic localization of the feeding effect of agouti-related peptide and alpha-melanocyte-stimulating hormone" <i>J. Clin. Invest.</i> , 105:1005-11 (2000).	
		KIM, et al., "The central melanocortin system affects the hypothalamopituitary thyroid axis and may mediate the effect of leptin" <i>Diabetes</i> , 49:177-82 (2000).	
		KIMMEL, et al., "Isolation and characterization of chicken insulin" <i>Endocrinology</i> , 83:1323-30 (1968).	
		KING, et al., "Regulation of neuropeptide Y release by neuropeptide Y receptor ligands calcium channel antagonists in hypothalamic slices" <i>J Neurochem.</i> , 73:641-6 (1999).	
		KIRBY, et al., "Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions" <i>J Med Chem</i> , 38:4579-86 (1995).	
		KIRBY, et al., "Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues," <i>J. Med. Chem.</i> , 36:385-93 (1993).	

Examiner's Signature	/Agnes Rooke/ (02/11/2008)	Date Considered	02/11/2008
----------------------	----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/501,411
				Filing Date	July 12, 2004
				First Named Inventor	Micheal Cowley
				Group Art Unit	
				Examiner Name	
Sheet	15	of	20	Attorney Docket Number	AI 9248US

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/AR/		KIRBY, et al., "Y1 and Y2 receptor selective neuropeptide Y analogues: Evidence of a Y1 receptor subclass" <i>J Med Chem</i> , 36:3802-08 (1993).	
		KOPELMAN, "Obesity as a medical problem," <i>Nature</i> , 404(6778):635-43 (2000).	
		KREYMANN, et al., "Developmental patterns of glucagon-like peptide-1-(7-36) amide and peptide-YY in rat pancreas and gut," <i>Endocrinology</i> , 129:1001-5 (1991).	
		KRUDE and GRUTERS, "Implications of proopiomelanocortin (POMC) mutations in humans: the POMC deficiency syndrome," <i>Trends Endocrinol. Metab.</i> , 11(1):15-22 (2000).	
		KRUDE, et al., "Sever early-onset obesity, adrenal insufficiency and red-hair pigmentation caused by POMC mutations in humans," <i>Nature Genetics</i> , 19:155-7 (1998).	
		LANGER, et al., "New methods of drug discovery," <i>Science</i> , 249:1527-1533 (1998)	
		LANGER, "Controlled release of macromolecules" <i>Chem. Tech.</i> , 12:98-105 (1982).	
		LANGER, et al., "Biocompatibility of polymeric delivery systems for macromolecules" <i>J. Biomed. Mater. Res.</i> , 15:167-277 (1981).	
		LEBAN, et al., "Novel modified carboxy terminal fragments of neuropeptide Y with high affinity for Y2-type receptors and potent functional antagonism at a Y1-type receptor" <i>J Med Chem</i> , 38:1150-57 (1995).	
		LIU, et al., "Synthetic peptide YY analog binds to a cell membrane receptor and delivers fluorescent dye to pancreatic cancer cells" <i>J Gastrointest Surg</i> , 5(2):147-52 (2001).	
		LIU, et al., "DNA elements with AT-rich core sequences direct pituitary cell-specific expression of the pro-opiomelanocortin gene in transgenic mice," <i>Biochem. J.</i> , 312(Pt 3):827-32 (1995).	
		LIU, et al., "Identification of DNA elements cooperatively activating proopiomelanocortin gene expression in the pituitary glands of transgenic mice," <i>Mol Cell Biol</i> , 12(9):3978-90 (1992).	
		LOW, et al., "Post-translational processing of proopiomelanocortin (POMC) in mouse pituitary melanotroph tumors induced by a POMC-simian virus 40 large T antigen transgene," <i>J. Biol. Chem.</i> , 268(33):24967-75 (1993).	

Examiner's Signature	/Agnes Rooke/ (02/11/2008)	Date Considered	02/11/2008
----------------------	----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/501,411
		Filing Date	July 12, 2004
		First Named Inventor	Micheal Cowley
		Group Art Unit	
		Examiner Name	
Sheet 16 of 20	Attorney Docket Number	AI 9248US	

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/AR/		LUNDBERG and MODIN, "Inhibition of sympathetic vasoconstriction in pigs <i>in vivo</i> by the neuropeptide Y-Y1 receptor antagonist BIBP 3226" <i>Br J Pharmacol</i> 116(7):2971-82 (1995).	
		LYZNICKI, et al., "Obesity: assessment and management in primary care," <i>Am Fam Physician.</i> , 63(11):2185-96 (2001).	
		MALAISSSE-LAGAE, et al., "Pancreatic polypeptide: a possible role in the regulation of food intake in the mouse: Hypothesis," <i>Experientia</i> , 33(7):915-7 (1977).	
		MALIK, et al., "Polyethylene glycol (PEG)-modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity," <i>Exp Hematol.</i> , 20(8):1028-35 (1992).	
		MALMSTROM, "Existence of both neuropeptide Y, Y1 and Y2 receptors in pig spleen evidence using subtype-selective antagonists <i>in vivo</i> " <i>Life Sci</i> , 69(17):1999-2005 (2001).	
		MALMSTROM, "Pharmacology of H 394/84, a dihydropyridine neuropeptide Y Y1 receptor antagonist, <i>in vivo</i> " <i>Eur J Pharmacol</i> , 418(1-2):95-104 (2001).	
		MARKS, et al., "Role of the central melanocortin system in cachexia," <i>Cancer Res.</i> , 61:1432-8 (2001).	
		MASSIE, "Obesity and heart failure--risk factor or mechanism?" <i>N Engl J Med.</i> , 347(5):358-9 (2002).	
		MCGOWAN and BLOOM, "Peptide YY and appetite control," <i>Curr Opin Pharmacol.</i> , 4(6):583-8 (2004).	
		MELEAGROS, et al., "Release of vasodilator, but not vasoconstrictor, neuropeptides and of enteroglucagon by intestinal ischaemia/reperfusion in the rat," <i>Gut</i> , 35:1701-6 (1994).	
		MORAN, et al., "Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys," <i>Am J Physiol Regul Integr Comp Physiol.</i> , 288(2):R384-8 (2005).	
		MORAN, "Cholecystokinin and satiety: Current perspectives" <i>Nutrition</i> , 16:858- 865 (2000).	
		MORGAN, et al., "Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat insulinoma cells," <i>Diabetologia</i> , 41:1482-91 (1998).	

Examiner's Signature	/Agnes Rooke/ (02/11/2008)	Date Considered	02/11/2008
----------------------	----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number		10/501,411
				Filing Date		July 12, 2004
				First Named Inventor		Micheal Cowley
				Group Art Unit		
				Examiner Name		
Sheet	17	of	20	Attorney Docket Number		AI 9248US

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/AR/		MORGAN, et al., "Reduced NPY induced feeding in diabetic but not steroid-treated rats: lack of evidence for changes in receptor number or affinity," <i>J Neuroendocrinol</i> , 8:283-90 (1996).	
		MORPURGO, et al., "Covalent modification of mushroom tyrosinase with different amphiphic polymers for pharmaceutical and biocatalysis applications," <i>Appl Biochem Biotechnol.</i> , 56(1):59-72 (1996).	
		NAVEILHAM, et al., "Attenuation of hypercholesterolemia and hyperglycemia in ob/ob mice by NPY Y2 receptor ablation," <i>Peptides</i> , 23(6):1087-91 (2002).	
		NAVEILHAN, et al., "Distinct roles of the Y1 and Y2 receptors on neuropeptide Y-induced sensitization to sedation," <i>J. Neurochem</i> , 78:1201-7 (2001).	
		NAVEILHAN, et al., "Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor," <i>Nature Medicine</i> , 5(10):1188-93 (1999).	
		NIGHTINGALE, et al., "Gastrointestinal hormones in short bowel syndrome. Peptide YY may be the 'colonic brake' to gastric emptying," <i>Gut</i> , 39:267-72 (1996).	
		OKADA, et al., Abstract 520, pg 180, 75 th Meeting of Endocrine Society (1993).	
		PEDERSEN-BJERGAARD, et al., "Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man" <i>Scand. J. Clin. Lab. Invest.</i> 56:497-503 (1996).	
		PITTNER, et al., "Effects of PYY[3-36] in rodent models of diabetes and obesity," <i>Int J Obes Relat Metab Disord.</i> , 28(8):963-71 (2004).	
		PLAYFORD, et al., "Comparison of the effects of transforming growth factor alpha and epidermal growth factor on gastrointestinal proliferation and hormone release," <i>Digestion</i> , 57:362-7 (1996).	
		PLAYFORD, et al., "Effects of peptide YY on the human cardiovascular system: reversal of responses to vasoactive intestinal peptide," <i>Am J Physiol.</i> 263(4 Pt 1):E740-7 (1992).	
		PLAYFORD, et al., "Preliminary report: role of peptide YY in defence against diarrhoea," <i>Lancet</i> , 335:1555-7, (1990).	

Examiner's Signature	/Agnes Rooke/ (02/11/2008)	Date Considered	02/11/2008
----------------------	----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/501,411
				Filing Date	July 12, 2004
				First Named Inventor	Micheal Cowley
				Group Art Unit	
				Examiner Name	
Sheet	18	of	20	Attorney Docket Number	AI 9248US

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/AR/		POTTER, et al., "A novel neuropeptide Y analog, N-acetyl[Leu28, Leu31]neuropeptide Y-(24-36), with functional specificity for the presynaptic (Y2) receptor" <i>Eur J Pharmacol</i> , 267(3):253-262 (1994).	
		POWIS, et al., "Leptin depolarizes rat hypothalamic paraventricular nucleus neurons," <i>Am J Physiol.</i> , 274(5 Pt 2):R1468-72 (1998).	
		QIN, et al., "Direct interaction of gbetagamma with a C-terminal gbetagamma-binding domain of the Ca ²⁺ channel alpha1 subunit is responsible for channel inhibition by G protein-coupled receptors," <i>PNAS</i> , 94(16):8866-71 (1997).	
		RABEN, et al., "The reproducibility of subjective appetite scores" <i>Br. J. Nutr.</i> , 73:517-30, (1995).	
		RISSANEN, et al., "Risk of disability and mortality due to overweight in a Finnish population," <i>BMJ</i> , 301(6756):835-7 (1990).	
		RIST, et al., "The bioactive conformation of neuropeptide Y analogues at the human Y2-receptor" <i>Eur J Biochem.</i> , 247:1019-1028 (1997).	
		ROSSI and BLOOM, "Central Nervous SYStem Neuropeptides Involved in Obesity," in <i>Handbook of Experimental Pharmacology</i> , pp 313-341; eds. D.H. Lockwood and T.G. Heffner, Springer, New York, (2000).	
		RUBINSTEIN, et al., "Rat and Mouse Proopiomelanocortin Gene Sequences Target Tissue-Specific Expression to the Pituitary Gland but not to the Hypothalamus of Transgenic Mice," <i>Neuroendocrinology</i> , 58:373-80 (1993).	
		SAUDEK, et al., "A preliminary trial of the programmable implantable medication system for insulin delivery" <i>N. Engl. J. Med.</i> , 321:574-9 (1989).	
		SAVAGE, et al., "Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers," <i>Gut</i> , 28:166-70 (1987).	
		SAVAGE, et al., "Is raised plasma peptide YY after intestinal resection in the rat responsible for the trophic response?" <i>Gut</i> , 26:1353-8 (1985).	
		SCHOBBER, "The neuropeptide Y Y1 antagonist, 1229U91, a potent agonist for the human pancreatic polypeptide-preferring (NPY Y4) receptor" <i>Peptides</i> , 19(3):537-42 (1998).	
		SCHUTZ, "Exercise and postprandial thermogenesis in obese women before and after weight loss," <i>Am J Clin Nutr.</i> , 45(6):1424-32 (1987).	

Examiner's Signature	/Agnes Rooke/ (02/11/2008)	Date Considered	02/11/2008
----------------------	----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/501,411
				Filing Date	July 12, 2004
				First Named Inventor	Micheal Cowley
				Group Art Unit	
				Examiner Name	
Sheet	19	of	20	Attorney Docket Number	AI 9248US

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/AR/		SCHWARTZ et al., "Central nervous system control of food intake" <i>Nature</i> , 404:661-671 (2000).	
		SEFTON, "Implantable pumps" <i>CRC Crit. Ref. Biomed. Eng.</i> , 14:201-40 (1987).	
		SHEIKH, et al., "Neuropeptide Y and peptide YY: major modulators of gastrointestinal blood flow and function" <i>Am J Physiol.</i> , 261:G701-15 (1991).	
		SHIRAISHI, et al., "Leptin effects on feeding-related hypothalamic and peripheral neuronal activities in normal and obese rats," <i>Nutrition</i> , 15:576-9 (1999).	
		SIDMAN, et al., "Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid" <i>Biopolymers</i> , 22:547-556 (1983).	
		SIMANOWSKI, et al., "Effects of acute and chronic ethanol administration on the gastrointestinal hormones gastrin, enteroglucagon, pancreatic glucagon and peptide YY in the rat," <i>Digestion</i> , 42:167-73 (1989).	
		SLUGG, et al., "Effect of the μ -Opioid Agonist DAMGO on Medial Basal Hypothalamic Neurons in Beta-Endorphin Knockout Mice," <i>Neuroendocrinology</i> , 72:208 (2000).	
		SMALL, et al., "Peptide analogue studies of the hypothalamic neuropeptide Y receptor mediating pituitary adrenocorticotrophic hormone release" <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 94:11686-91 (1997).	
		SODERBERG, et al., "Zebrafish genes for neuropeptide Y and peptide YY reveal origin by chromosome duplication from an ancestral gene linked to the homeobox cluster" <i>J. Neurochem.</i> , 75:908-18 (2000).	
		SOLL, et al., "Novel analogues of neuropeptide Y with a preference for the Y1-receptor" <i>Eur J Biochem</i> , 268(10):2828-37 (2001).	
		SPANSWICK, et al., "Leptin inhibits hypothalamic neurons by activation of ATP-sensitive potassium channels," <i>Nature</i> , 390:521-5 (1997).	
		SPILLER, et al., "Further characterisation of the 'ileal brake' reflex in man--effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY," <i>Gut</i> , 29:1042-51 (1988).	
		TARLING, et al., "A model gastric emptying using paracetamol absorption in intensive care patients" <i>Intensive Care Med.</i> , 23:256-260 (1997).	
Examiner's Signature	/Agnes Rooke/ (02/11/2008)		Date Considered
			02/11/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/501,411
				Filing Date	July 12, 2004
				First Named Inventor	Micheal Cowley
				Group Art Unit	
				Examiner Name	
Sheet	20	of	20	Attorney Docket Number	AI 9248US

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/AR/		TATEMOTO, et al., "Neuropeptide Y: Complete amino acid sequence of the brain peptide" <i>Proc Natl Acad Sci U.S.A.</i> , 79:5485-9 (1982).	
		TSUKADA, et al., "Functional analysis of the cell-specific enhancer in the human proopiomelanocortin gene by beta-galactosidase histochemical staining," <i>DNA and Cell Biol.</i> , 13(7):755-62 (1994).	
		VERMA, et al., "Human fos gene," <i>Cold Spring Harb Symp Quant Biol.</i> , 51:949-58 (1986).	
		VOROBJEV, et al., "Oligonucleotide conjugated to linear and branched high molecular weight polyethylene glycol as substrates for RNase H," <i>Nucleosides & Nucleotides</i> , 18(11-12):2745-50 (1999).	
		WALKER, et al., "Neuropeptide Y modulates Neurotransmitter Release and Ca ²⁺ Currents in Rat Sensory Neurons," <i>J. Neuroscience</i> , 8:2438-2446 (1988).	
		WANG and HANSON, "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers," <i>Journal of Parenteral Science and technical Technology</i> , 42:S4-S26 (1988).	
		WARDLAW, et al., "Obesity as a Neuroendocrine Disease: Lessons to Be Learned from Proopiomelanocortin and Melanocortin Receptor Mutations in Mice and Men," <i>J. Clin. Endocrin. & Metab.</i> , 86(4):1442-46 (2001).	
		YOSHINAGA, et al., "Structural requirements of peptide YY for biological activity at enteric sites," <i>Am. J. Physiol. Gastrointest. Liver Physiol.</i> , 263:G695-701 (1992).	
		YOUNG, et al., "Authentic cell-specific and developmentally regulated expression of pro-opiomelanocortin genomic fragments in hypothalamic and hindbrain neurons of transgenic mice," <i>J. Neurosci.</i> , 18:6631-40 (1998).	
		ZHANG, et al., "Positional cloning of the mouse <i>obese</i> gene and its human homologue," <i>Nature</i> , 372:425 (1994).	

Examiner's Signature	/Agnes Rooke/ (02/11/2008)	Date Considered	02/11/2008
----------------------	----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.